Cargando…

Identification of AIM2 as a downstream target of JAK2V617F

BACKGROUND: The gain-of-function mutation JAK2V617F is frequently found in Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) patients. However, the tumorigenic properties of JAK2V617F have mostly been characterized in in vivo and in vitro murine models due to the lack of appropriate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liew, Ei Leen, Araki, Marito, Hironaka, Yumi, Mori, Seiichi, Tan, Tuan Zea, Morishita, Soji, Edahiro, Yoko, Ohsaka, Akimichi, Komatsu, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730608/ https://www.ncbi.nlm.nih.gov/pubmed/26823993 http://dx.doi.org/10.1186/s40164-016-0032-7

Ejemplares similares

Melting Curve Analysis after T Allele Enrichment (MelcaTle) as a Highly Sensitive and Reliable Method for Detecting the JAK2V617F Mutation
por: Morishita, Soji, et al.
Publicado: (2015)

Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells
por: Sunami, Yoshitaka, et al.
Publicado: (2013)

Correction: Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells
por: Sunami, Yoshitaka, et al.
Publicado: (2013)

Detection of MPLW515L/K Mutations and Determination of Allele Frequencies with a Single-Tube PCR Assay
por: Takei, Hiraku, et al.
Publicado: (2014)

Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
por: Edahiro, Yoko, et al.
Publicado: (2022)

CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome–negative myeloproliferative neoplasms
por: Morishita, Soji, et al.
Publicado: (2020)

Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin
por: Edahiro, Yoko, et al.
Publicado: (2020)

Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide
por: Watanabe, Naoki, et al.
Publicado: (2017)

Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non‐neoplastic erythrocytosis patients
por: Mori, Yosuke, et al.
Publicado: (2022)

Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms
por: Araki, Marito, et al.
Publicado: (2017)

Mutant molecular chaperone activates cytokine receptor as a homomultimer
por: Araki, Marito, et al.
Publicado: (2018)

Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
por: Inano, Tadaaki, et al.
Publicado: (2021)

Author Correction: Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
por: Inano, Tadaaki, et al.
Publicado: (2022)

Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms
por: Morishita, Soji, et al.
Publicado: (2023)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Hematopoietic JAK2(V617F)-mediated clonal hematopoiesis: AIM2 understand mechanisms of atherogenesis
por: Sano, Soichi, et al.
Publicado: (2021)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia
por: Baba, Tomohisa, et al.
Publicado: (2013)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

International external quality assurance of JAK2 V617F quantification
por: Asp, Julia, et al.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA
por: Kimura, Konobu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_toleecuks7m48sivr1dbnnqscq